CRISPR Therapeutics' (CRSP) CEO Sam Kulkarni on Cowen 42nd Annual Health Care Conference (Transcript)Seeking Alpha • 03/07/22
Peloton Isn't the ONLY Takeover Target. What Companies Could Be Bought Out in 2022?InvestorPlace • 02/23/22
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/15/22
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/09/22
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should KnowZacks Investment Research • 02/08/22
Crispr Therapeutics begins dosing patients in Phase 1 trial for experimental type 1 diabetes treatmentMarket Watch • 02/02/22
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)GlobeNewsWire • 02/02/22
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should KnowZacks Investment Research • 01/29/22